Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation

Creative Commons License

DE LA MORENA M. T. , LEONARD D., Torgerson T. R. , CABRAL-MARQUES O., SLATTER M., AGHAMOHAMMADI A., ...Daha Fazla

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, cilt.139, ss.1282-1292, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 139 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.jaci.2016.07.039
  • Dergi Adı: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
  • Sayfa Sayıları: ss.1282-1292

Özet

Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients.